Tuberculosis treatment and resulting abnormal blood glucose: a scoping review of studies from 1981 - 2021.
Diabetes
human immunodeficiency virus
hyperglycaemia
impaired glucose tolerance
Journal
Global health action
ISSN: 1654-9880
Titre abrégé: Glob Health Action
Pays: United States
ID NLM: 101496665
Informations de publication
Date de publication:
31 12 2022
31 12 2022
Historique:
entrez:
30
9
2022
pubmed:
1
10
2022
medline:
5
10
2022
Statut:
ppublish
Résumé
Hyperglycaemia is a risk factor for tuberculosis. Evidence of changes in blood glucose levels during and after tuberculosis treatment is unclear. To compile evidence of changes in blood glucose during and after tuberculosis treatment and the effects of elevated blood glucose changes on treatment outcomes in previously normoglycaemic patients. Original research studies (1980 to 2021) were identified in PubMed, Web of Science, CINAHL and Embase databases. Of the 1,277 articles extracted, 14 were included in the final review. All the studies were observational and 50% were prospective. Fasting blood sugar was the most common clinical test (64%), followed by the glycated haemoglobin test and the oral glucose tolerance test (each 50%). Most tests were conducted at baseline and in the third month of treatment. Twelve studies showed that the prevalence of hyperglycaemia in previously normoglycaemic patients decreased from baseline to follow-up and end of treatment. Three studies showed successful treatment outcomes of 64%, 75% and 95%. Patients with hyperglycaemia at baseline were more likely to develop cavitary lung lesions and poor treatment outcomes and had higher post-treatment mortality. There was no difference in outcomes by human immunodeficiency virus (HIV) status. Elevated blood glucose in normoglycaemic patients receiving treatment for tuberculosis decreased by the end of treatment. Positive HIV status did not affect glucose changes during treatment. Further research is needed to investigate post-treatment morbidity in patients with baseline hyperglycaemia and the effects of HIV on the association between blood glucose and tuberculosis.
Sections du résumé
BACKGROUND
Hyperglycaemia is a risk factor for tuberculosis. Evidence of changes in blood glucose levels during and after tuberculosis treatment is unclear.
OBJECTIVE
To compile evidence of changes in blood glucose during and after tuberculosis treatment and the effects of elevated blood glucose changes on treatment outcomes in previously normoglycaemic patients.
METHODS
Original research studies (1980 to 2021) were identified in PubMed, Web of Science, CINAHL and Embase databases.
RESULTS
Of the 1,277 articles extracted, 14 were included in the final review. All the studies were observational and 50% were prospective. Fasting blood sugar was the most common clinical test (64%), followed by the glycated haemoglobin test and the oral glucose tolerance test (each 50%). Most tests were conducted at baseline and in the third month of treatment. Twelve studies showed that the prevalence of hyperglycaemia in previously normoglycaemic patients decreased from baseline to follow-up and end of treatment. Three studies showed successful treatment outcomes of 64%, 75% and 95%. Patients with hyperglycaemia at baseline were more likely to develop cavitary lung lesions and poor treatment outcomes and had higher post-treatment mortality. There was no difference in outcomes by human immunodeficiency virus (HIV) status.
CONCLUSION
Elevated blood glucose in normoglycaemic patients receiving treatment for tuberculosis decreased by the end of treatment. Positive HIV status did not affect glucose changes during treatment. Further research is needed to investigate post-treatment morbidity in patients with baseline hyperglycaemia and the effects of HIV on the association between blood glucose and tuberculosis.
Identifiants
pubmed: 36178364
doi: 10.1080/16549716.2022.2114146
pmc: PMC9543146
doi:
Substances chimiques
Blood Glucose
0
Glycated Hemoglobin A
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2114146Références
Monaldi Arch Chest Dis. 1999 Aug;54(4):307-10
pubmed: 10546470
J Diabetes Metab Disord. 2014 Dec 16;13(1):123
pubmed: 25551103
PLoS One. 2011;6(8):e24215
pubmed: 21912626
Trop Med Int Health. 2013 Jul;18(7):822-9
pubmed: 23648145
Int J Tuberc Lung Dis. 2019 Jul 1;23(7):783-796
pubmed: 31439109
BMC Health Serv Res. 2020 Apr 19;20(1):328
pubmed: 32306961
Indian J Med Res. 2019 Mar;149(3):384-388
pubmed: 31249204
Clin Microbiol Rev. 2020 Jul 1;33(4):
pubmed: 32611585
Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28
pubmed: 30559228
Int J Infect Dis. 2018 Apr;69:11-19
pubmed: 29253707
J Immunol Res. 2022 Jun 1;2022:6837745
pubmed: 35692502
Glob Health Action. 2017;10(1):1289737
pubmed: 28470109
Clin Infect Dis. 2020 Aug 14;71(4):1080-1088
pubmed: 31557282
Clin Med Insights Circ Respir Pulm Med. 2021 Sep 20;15:11795484211039830
pubmed: 34566441
Eur Respir J. 2017 Jul 20;50(1):
pubmed: 28729474
Int J Infect Dis. 2019 Jul;84:127-130
pubmed: 31085315
BMC Infect Dis. 2019 Mar 13;19(1):254
pubmed: 30866836
BMC Infect Dis. 2019 Oct 29;19(1):915
pubmed: 31664936
J Pak Med Assoc. 1995 Sep;45(9):237-8
pubmed: 8683828
J Infect Dis. 2016 Apr 1;213(7):1163-72
pubmed: 26609005
Syst Rev. 2019 Sep 11;8(1):234
pubmed: 31511077
Tubercle. 1990 Jun;71(2):135-8
pubmed: 2219464
Curr Diab Rep. 2018 Aug 9;18(9):71
pubmed: 30090969
J Clin Tuberc Other Mycobact Dis. 2019 Nov 01;17:100128
pubmed: 31788570
Thorax. 2013 Mar;68(3):214-20
pubmed: 23250998
Sci Rep. 2017 Mar 10;7:44205
pubmed: 28281682
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Lancet Glob Health. 2019 Apr;7(4):e448-e460
pubmed: 30819531
J Infect Dis. 2022 Feb 15;225(4):617-626
pubmed: 34651642
Int J Tuberc Lung Dis. 2005 Jul;9(7):777-83
pubmed: 16013774
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):535-545
pubmed: 32408118
BMJ. 1990 Jan 13;300(6717):63-5
pubmed: 2105772
BMC Med. 2011 Jul 01;9:81
pubmed: 21722362
Tuberc Res Treat. 2017;2017:1702578
pubmed: 29270319